TGFB1 and pulmonary fibrosis: For example, recent clinical trials of molecules inhibiting TGF-β and pirfenidone, a first in-class anti-fibrotic small molecule approved for idiopathic pulmonary fibrosis treatment, reported limited efficacy for kidney fibrosis [30].